Chase GSK for possibility of DHODH assay on best compounds about osm_to_do_list HOT 4 CLOSED

can this be grouped with the TB compounds? Should we not essentially be screening as much as we can against as much as we can? Stock of compound and the amount of work GSK can should be our only limiting factors.

from osm_to_do_list.

Yes indeed. If we can screen for TB we can send all at the same time, but GSK already have some of our earlier arylpyrroles (the ones included in Ian Wallace's prediction of activity) and the nature of the assay is obviously different to a bioactivity screen. I need to ping GSK on availability of compound and people to run the assay.

from osm_to_do_list.

I pinged GSK about whether the original compounds were tested last year. There is the possibility that we could re-do the in silico prediction with the enhanced set of compounds we have now made in that series and see if we get the same outcome. But representative compounds physically being evaluated might be enough.

from osm_to_do_list.

This was carried out for Series 1 here, with data going into the Series 1 paper, so closing.

from osm_to_do_list.